Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 16/20 | 0.67 |
| ▸ | INSR | P06213 | 3/20 | 0.67 |
| ▸ | MET | P08581 | 11/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31251235 | 0.90 | ALK (0.54) | ALKINSRMETPTK2HDAC1 | |
| SCHEMBL32690354 | 0.88 | ALK (0.66) | ALKINSRMETPTK2 | |
| SCHEMBL32690343 | 0.87 | ALK (0.59) | ALKINSRMETPTK2 | |
| SCHEMBL32690306 | 0.86 | INSR (0.67) | ALKINSRMET | |
| SCHEMBL886444 | 0.84 | ALK (0.60) | ALKINSRMETPTK2 | |
| SCHEMBL32690395 | 0.83 | CDK7 (0.53) | ALKINSRMETPTK2HDAC1 | |
| SCHEMBL32690358 | 0.81 | CDK7 (0.53) | ALKINSRMETPTK2HDAC1 | |
| SCHEMBL885817 | 0.80 | INSR (1.00) | ALKINSRMETPTK2 | |
| SCHEMBL11916626 | 0.80 | ALK (0.77) | ALKMETPTK2HDAC1HDAC2 | |
| SCHEMBL18350626 | 0.80 | ALK (0.83) | ALKINSRMETHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | UNOGEN BIOTECH LTD (US) | 2026-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | ALK, ERBB2, ERBB3 | ALK 1/4885INSR 314/4885MET 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.